Navigation Links
Cell Therapeutics, Inc. Announces Authorization to Publish Italian Listing Prospectus
Date:1/11/2008

SEATTLE, Jan. 11 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTAX: CTIC) today announced that the Commissione Nazionale per le Societa e la Borsa ("CONSOB") granted authorization to publish the Italian listing prospectus, according to the procedures set forth by Article 8 and Article 56 of the CONSOB Regulation no. 11971/99, relating to offerings of CTI's common stock representing more than 10% of the shares of common stock currently outstanding pursuant to the Step-Up Equity Financing Agreement by and between Societe Generale and CTI, subject to the inclusion of certain additional information in the prospectus.

Societe Generale has agreed to purchase, over a period of time through January 2009, up to 60 million Euros worth of shares of CTI's common stock. Any shares issued, which are covered under an existing shelf registration, will be purchased by Societe Generale, which will sell the shares on the Italian market. Societe Generale's obligation to purchase shares upon request by CTI is subject to the conditions set forth in the agreement with the bank.

Subject to certain conditions, the Step-up Equity Financing Agreement will allow CTI to raise equity finance in one or more tranches. All issuances are at CTI's election, and CTI is not required to undertake any issuances under the agreement. The total amount of any capital raised will depend on the actual financing needs over the lifetime of the agreement and other considerations and will reflect the market performance and trading volume of CTI shares.

As soon as published, the listing prospectus will be available in hard copy form at CTI's office in Italy at Via Ariosto, 23, 20091 Bresso (MI) and at the head office of Borsa Italiana S.p.A. at Piazza degli Affari, 6, Milan; and in electronic form on CTI's web site (http://www.cticseattle.com).

About Cell Therapeutics, Inc.

Headquartered in Seattl
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cell Therapeutics, Inc. (CTI) Hosts Conference Call to Discuss Update on Zevalin(R) Acquisition, CMS Reimbursement, and PIX301 Timeline
2. Pearl Therapeutics, Inc. Expands Its Senior Management Team With Top Talent in Clinical Development and Regulatory Affairs
3. Cell Therapeutics, Inc. (CTI) to Submit Marketing Authorization Application for XYOTAX(TM) for First-line Non-small Cell Lung Cancer Ahead of Schedule
4. Cell Therapeutics, Inc. Announces Issuance of $23.25 Million in New Convertible Senior Notes in Exchange for $36.08 Million of Existing Convertible Senior Subordinated and Subordinated Notes
5. ARYx Therapeutics, Inc. Announces Pricing of its Initial Public Offering
6. Bioenergy Life Science and Integrative Therapeutics, Inc. Form Exclusive Co-Marketing Alliance
7. Velcura Therapeutics, Inc. Appoints Industry Executive to Lead Regulatory Affairs
8. Cell Therapeutics, Inc. (CTI) BIO Presentation to Be Webcast
9. Hyperion Therapeutics, Inc. Announces Senior Management Team and $15M Financing Event
10. Nile Therapeutics, Inc. to Present at Upcoming BIO Investor Forum
11. Northwest Biotherapeutics, Inc. Announces Appointment of Chief Financial Officer

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)..., , COPENHAGEN, Dec. 2 The ...ith BioIsoprene technology, a breakthrough alterna...ent in the manufacture of synthetic rubber with re...enmark, this week. One tire will be on display at ...hagen International Airport throughout December 21...
(Date:12/2/2009)..., , LELYSTAD, The Netherlands, December...ands based biotechnology company focusing on prote...ne therapeutics today announced that it,has appoin...icer. , Dr. Mol will be responsible for a... management and strategic direction of the company...
(Date:12/2/2009)..., , RESTON, Va., Dec. 2 /PRNewswire-A...iry" or the "Company") (OTC Bulletin Board: EMDY),...children,s formula, milk powder and,soybean produc... be featured,in the Spring issue of US Food & ...rship of over 250,000 executives in the food and b...
(Date:12/2/2009)... The Scientist, a leading s...ked Photometrics’ Evolve “Intelligent&...squo;s “Top 10 Innovations of 2009. , ... Evolve ™ EMCCD camera from Photometrics ...ance CCD and EMCCD cameras for the life sciences, ...
Breaking Biology Technology:The World's First Goodyear Concept Tires Made with BioIsoprene(TM) Technology Arrive in Copenhagen in time for United Nations Climate Change Conference 2The World's First Goodyear Concept Tires Made with BioIsoprene(TM) Technology Arrive in Copenhagen in time for United Nations Climate Change Conference 3Dutch Biotech Company Pepscan Appoints New CEO 2Emerald Dairy To Be Featured in Spring Issue of US Food and Drink Executive 2The Scientist Names Photometrics' Evolve EMCCD Camera One of the “Top 10 Innovations” of 2009 2The Scientist Names Photometrics' Evolve EMCCD Camera One of the “Top 10 Innovations” of 2009 3
...other twist on the strangeness of the nanoworld, r...and Technology (NIST) and the University of Maryla...h as silica that are quite brittle in bulk form be...sults may affect the design of future nanomachines... Kim and colleagues first demonstrated* the latest...
...CELAND, March 12 deCODE genetics,(Nasdaq: DCGN )...s for the,quarter and year ended December 31, 2007...and operating highlights will be webcast live tomo... (details below)., Net loss for the year ended De...5 million for the full year 2006. Basic and dilute...
...N JOSE, Calif., March 12 Oncolys BioPharma,Inc. (...ose, CA, USA),announced today that they have enter... to develop and commercialize throughout Asia, Tac...rus (HCV) compound, TT-033,code-named by Oncolys a...gic alliance entered into by Tacere and Oncolys in...
Other Biology Technology:Nanomaterials show unexpected strength under stress 2deCODE Genetics Announces Full-year 2007 Financial Results 2deCODE Genetics Announces Full-year 2007 Financial Results 3deCODE Genetics Announces Full-year 2007 Financial Results 4deCODE Genetics Announces Full-year 2007 Financial Results 5deCODE Genetics Announces Full-year 2007 Financial Results 6deCODE Genetics Announces Full-year 2007 Financial Results 7deCODE Genetics Announces Full-year 2007 Financial Results 8deCODE Genetics Announces Full-year 2007 Financial Results 9Oncolys BioPharma and Tacere Therapeutics Sign Strategic Alliance and License Agreement to Develop and Commercialize RNAi Hepatitis C Drug 2Oncolys BioPharma and Tacere Therapeutics Sign Strategic Alliance and License Agreement to Develop and Commercialize RNAi Hepatitis C Drug 3
(Date:12/1/2009)...sease, nerve cell degeneration plays a crucial rol...ibly be derived from steering the generation and/o...blished in the current issue of the renowned journ...go, neurogenesis the process of nerve cell develo...t brain. The textbooks asserted that dead nerve ce...
(Date:12/1/2009)...hnology has been awarded a U.S. Air Force Center o...arvesting and adaptive materials, and to develop t...he modern warfighter. , The $10.5 million Cente... Nanostructures and Improved Cognition (BIONIC) ce... Sandhage, professors in Georgia Tech,s School of ...
(Date:12/1/2009)... attacks by sharks can be solved with a new techni...mp they put on their victims, according to a Unive...In a method analogous to analyzing human fingerpri...ely comparing shark bites to the jaws and teeth of...ctor of the International Shark Attack File, which...
Breaking Biology News(10 mins):New source discovered for the generation of nerve cells in the brain 2Air Force Center of Excellence awarded in nanostructures and improved cognition 2Air Force Center of Excellence awarded in nanostructures and improved cognition 3Air Force Center of Excellence awarded in nanostructures and improved cognition 4New forensic technique gives clues about sharks from bite damage 2New forensic technique gives clues about sharks from bite damage 3Traveling With Diabetes The Positive Way 55962 1Traveling With Diabetes The Positive Way 55962 2Traveling With Diabetes The Positive Way 55962 3Two Year SYNTAX Data Show Comparable Safety Outcomes for Complex Patients Treated With TAXUS 28R 29 EXPRESS 28R 29 Stents and Bypass Surgery 4934 1Two Year SYNTAX Data Show Comparable Safety Outcomes for Complex Patients Treated With TAXUS 28R 29 EXPRESS 28R 29 Stents and Bypass Surgery 4934 2Two Year SYNTAX Data Show Comparable Safety Outcomes for Complex Patients Treated With TAXUS 28R 29 EXPRESS 28R 29 Stents and Bypass Surgery 4934 3Two Year SYNTAX Data Show Comparable Safety Outcomes for Complex Patients Treated With TAXUS 28R 29 EXPRESS 28R 29 Stents and Bypass Surgery 4934 4Two Year SYNTAX Data Show Comparable Safety Outcomes for Complex Patients Treated With TAXUS 28R 29 EXPRESS 28R 29 Stents and Bypass Surgery 4934 5SOKO Fitness 26 Spa Group Announces Record Financial Results for Fiscal Year 3B Sets Conference Call to Discuss Results 55954 1SOKO Fitness 26 Spa Group Announces Record Financial Results for Fiscal Year 3B Sets Conference Call to Discuss Results 55954 2SOKO Fitness 26 Spa Group Announces Record Financial Results for Fiscal Year 3B Sets Conference Call to Discuss Results 55954 3SOKO Fitness 26 Spa Group Announces Record Financial Results for Fiscal Year 3B Sets Conference Call to Discuss Results 55954 4SOKO Fitness 26 Spa Group Announces Record Financial Results for Fiscal Year 3B Sets Conference Call to Discuss Results 55954 5SOKO Fitness 26 Spa Group Announces Record Financial Results for Fiscal Year 3B Sets Conference Call to Discuss Results 55954 6SOKO Fitness 26 Spa Group Announces Record Financial Results for Fiscal Year 3B Sets Conference Call to Discuss Results 55954 7SOKO Fitness 26 Spa Group Announces Record Financial Results for Fiscal Year 3B Sets Conference Call to Discuss Results 55954 8SOKO Fitness 26 Spa Group Announces Record Financial Results for Fiscal Year 3B Sets Conference Call to Discuss Results 55954 9
...ding on newly discovered genetic threads in the ri...er, a Johns Hopkins Kimmel Cancer Center team has ... those signals with a statin and an experimental a...ol-lowering lovastatin and cyclopamine killed 63 p...atory. By contrast, using either agent alone wipe...
...ct detection of base sequence in duplex nucleic ac...s Research will publish "Heteropolymeric Triplex-B...Nucleotide Polymorphisms in Human Genomic Samples"...r-reviewed, open access, online journal, PLoS ONE....elating to the assay of pathogens in samples also ...
...ntists at Rice University and pediatric specialist...new way to use Rice,s famed buckyball nanoparticle...lls. , The research appears in the Jan. 21 issue o... , All living cells defend themselves by walling...form a protective cocoon around the cell,s inner m...
Other Biology News:Statin plus cancer drug deliver combo punch to brain cancer cells 2Triplex assay used to assay duplex genomic DNA 2Buckyballs used as 'passkey' into cancer cells 2
Terrific Broth from GE Healthcare, formerly Amersham Biosciences
Mouse Anti-Human VEGF R3 / Flt-4 Monoclonal Antibody, Phycoerythrin Conjugated, Clone 54733 from R&D Systems
Goat Anti-Human Legumain Polyclonal Antibodies, from R&D Systems
Mouse Anti-Human Cystatin F Monoclonal Antibodies, 292103 from R&D Systems
Biology Products: